CD8A and non-small cell lung carcinoma: This role has also been described at the intratumoral level: in NSCLC patients, this interaction leads to PD-L1 ingestion and presentation on the platelets’ surface, in the TME, and in the bloodstream, resulting in CD4+ and CD8+ inhibition [133].